In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...

Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...